Received: 23 August 2018
Accepted: 22 January 2019
First Online: 11 February 2019
Ethics approval and consent to participate
: The Ethics Committee Research University Hospitals Leuven, Belgium (OG032) approved this study (S61615).The need for informed consent was waived by the Clinical Trial Centre of the University Hospitals Leuven as this quality-improvement study was set up as standard practice. Advices will be provided by the clinical pharmacist directly the treating physician, who will finally decide on treatment adaptation. Each hospitalized patient is eligible for inclusion in the CMA service. No exclusion criteria are defined. Patients will not provide informed consent as this service will be implemented as standard of care.
: Not applicable.
: All authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.